Active pharmaceutical ingredients (APIs)

Active pharmaceutical ingredients (APIs)
Product Description

High quality APIs to accelerate your generic product launches. Catering to leading innovator and generic companies across the world, Dr. Reddy’s is recognized as one of the largest API suppliers worldwide. The launch of Dr. Reddy’s XCEED – a digital customer service platform - gives customers instant access to an industry leading portfolio which spans across a wide range of indications and complex molecules such as steroids, peptides or highly potent, APIs (HPAPI). Customers across the globe are able to manage the whole business process in real time, from ordering samples to submit and track their orders, but also to closely interact with Dr. Reddy’s interdisciplinary support team and much more. For more information, log on to: api.drreddys.com

Read more Show less

Dr. Reddy's Laboratories SA

  • CH
  • 2015
    On CPHI since
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Quality Service
  • Supplied from
    India; Mexico; Switzerland; United Kingdom
More specifications Fewer specifications
Sales Markets
Show more Show less

Dr. Reddy's Laboratories SA

  • CH
  • 2015
    On CPHI since
View company profile

More Products from Dr. Reddy's Laboratories SA (4)

  • Losartan Potassium

    Product Losartan Potassium

    Dr. Reddy’s has the capabilities and capacities to manufacture and deliver sartan APIs in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements of the...
  • Valsartan

    Product Valsartan

    Dr. Reddy’s has the capabilities and capacities to manufacture and deliver sartan APIs in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements of the...
  • Irbesartan

    Product Irbesartan

    Dr. Reddy’s has the capabilities and capacities to manufacture and deliver Irbesartan APIs in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements of...
  • Telmisartan

    Product Telmisartan

    Dr. Reddy’s has the capabilities and capacities to manufacture and deliver Telmisartan in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements of the...

Dr. Reddy's Laboratories SA resources (4)

  • Pharma Explained: Active Pharmaceutical Ingredients

    News Pharma Explained: Active Pharmaceutical Ingredients

    What are APIs? As the name suggests, Active Pharmaceutical Ingredients (APIs) are the heart of any dosage form, whether they are oral, injectable or inhaled, and are absolutely essential to the development of a formulated product.
    11 Mar 2021
  • Dabired (Dabigatran Pellets)

    Brochure Dabired (Dabigatran Pellets)

    Dabired is ready to fill Dabigatran Etexilate Mesylate 42.04% w/w pellets which are designed to integrate seamlessly into your encapsulation process.
  • Sacubitril/Valsartan (LCZ696) Whitepaper

    Whitepaper Sacubitril/Valsartan (LCZ696) Whitepaper

    This whitepaper outlines Dr. Reddy’s development and characterization approach for the API and how formulation success and early market reach can be facilitated.
  • Innovation Across Borders: How Pharma and innovators are fighting back against COVID-19 and ways forward

    Video Innovation Across Borders: How Pharma and innovators are fighting back against COVID-19 and ways forward

    A global pandemic demands a fast response. The research-based pharmaceutical industry is working upstream at extraordinary speed to develop a safe and effective vaccine for COVID19. Pharmaceutical companies around the globe are joining forces and speeding up the process by conducting phases and development in parallel and forging new partnerships and collaboration. The pharmaceutical and life science industry has faced the need to leverage science and technology, developed pre and during the pandemic. Firms are coming up with new ways to maintain production despite disrupted supply chains, or they are mobilizing to design new products as demand for existing products collapses. This discussion will examine how the COVID-19 pandemic is driving pharma and life science companies to collaborate, innovate and prepare for an uncertain future. This webinar was originally aired as part of the CPHI Festival of Pharma.